A Phase I, Open-label, Parallel-group, Mono-center Trial to Investigate the Pharmacokinetics of a Single Intravenous Dose of Cilengitide in Subjects With Mild, Moderate or Severe Renal Impairment Compared to Subjects With Normal Renal Function.

Trial Profile

A Phase I, Open-label, Parallel-group, Mono-center Trial to Investigate the Pharmacokinetics of a Single Intravenous Dose of Cilengitide in Subjects With Mild, Moderate or Severe Renal Impairment Compared to Subjects With Normal Renal Function.

Completed
Phase of Trial: Phase I

Latest Information Update: 27 Apr 2012

At a glance

  • Drugs Cilengitide (Primary)
  • Indications Glioblastoma; Head and neck cancer; Lymphoma; Non-small cell lung cancer; Prostate cancer; Solid tumours
  • Focus Pharmacokinetics
  • Sponsors Merck KGaA
  • Most Recent Events

    • 27 Apr 2012 Actual patient number 32 added as reported by ClinicalTrials.gov.
    • 27 Apr 2012 Actual end date Apr 2012 added as reported by ClinicalTrials.gov.
    • 27 Apr 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top